A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation

Rees Lesley; Tizard E. Jane; AJ Morgan; Cubitt W. David; S Finerty; Oyewole-Eletu Tintilade A.; Owen Karen; Royed Collin; Stevens Servi J.; Schroff Rushana C.; Tanday Manjit K.; AD Wilson; Middeldorp Jaap M.; Amlot Peter L.; Steven Neil M.

doi:10.1097/TP.0b013e3181b9d918

A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation

Rees Lesley, Tizard E. Jane, AJ Morgan, Cubitt W. David, S Finerty, Oyewole-Eletu Tintilade A., Owen Karen, Royed Collin, Stevens Servi J., Schroff Rushana C., Tanday Manjit K., AD Wilson, Middeldorp Jaap M., Amlot Peter L., Steven Neil M.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

105 Citations (Scopus)

Abstract

Vaccination against Epstein-Barr virus (EBV), inducing an antibody response to the envelope glycoprotein gp350,might protect EBV-negative children with chronic kidney disease from lymphoproliferative disease after transplantation. A phase I trial recruited children with chronic kidney disease to two successive cohorts given three injections of 12.5 µg (n=6) and 25 µg (n=10) recombinant gp350/alhydrogel vaccine more than 6 to 8 weeks. One in each cohort acquired wild EBV before the week 28 evaluation. Both doses were similarly immunogenic, inducing an IgG response in all 13 evaluable patients. Neutralizing antibodies were detected in four recipients (1/4 in the 12.5µg and 3/9 in the 25 µg cohort). Median time from first vaccination to transplantation was 24 weeks. Immune responses declined rapidly and were unlikely to affect posttransplant events. The vaccine was immunogenic but prolonged vaccination to time of transplantation, or improved adjuvants are required in future trials to reduce posttransplant EBV load and risk of lymphoproliferative disease.

Translated title of the contribution	A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation
Original language	English
Pages (from-to)	1025 - 1029
Number of pages	5
Journal	Transplantation
Volume	88
Issue number	8
DOIs	https://doi.org/10.1097/TP.0b013e3181b9d918
Publication status	Published - Oct 2009

Bibliographical note

Publisher: Lippincott Williams & Wilkins

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/TP.0b013e3181b9d918

http://www.transplantjournal.com

Handle.net

Persistent link

Cite this

Lesley, R., E. Jane, T., Morgan, AJ., W. David, C., Finerty, S., Tintilade A., O.-E., Karen, O., Collin, R., Servi J., S., Rushana C., S., Manjit K., T., Wilson, AD., Jaap M., M., Peter L., A., & Neil M., S. (2009). A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation. Transplantation, 88(8), 1025 - 1029. https://doi.org/10.1097/TP.0b013e3181b9d918

@article{69c130519bff4813872a5aaab6fae749,

title = "A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation",

abstract = "Vaccination against Epstein-Barr virus (EBV), inducing an antibody response to the envelope glycoprotein gp350,might protect EBV-negative children with chronic kidney disease from lymphoproliferative disease after transplantation. A phase I trial recruited children with chronic kidney disease to two successive cohorts given three injections of 12.5 µg (n=6) and 25 µg (n=10) recombinant gp350/alhydrogel vaccine more than 6 to 8 weeks. One in each cohort acquired wild EBV before the week 28 evaluation. Both doses were similarly immunogenic, inducing an IgG response in all 13 evaluable patients. Neutralizing antibodies were detected in four recipients (1/4 in the 12.5µg and 3/9 in the 25 µg cohort). Median time from first vaccination to transplantation was 24 weeks. Immune responses declined rapidly and were unlikely to affect posttransplant events. The vaccine was immunogenic but prolonged vaccination to time of transplantation, or improved adjuvants are required in future trials to reduce posttransplant EBV load and risk of lymphoproliferative disease.",

author = "Rees Lesley and {E. Jane}, Tizard and AJ Morgan and {W. David}, Cubitt and S Finerty and {Tintilade A.}, Oyewole-Eletu and Owen Karen and Royed Collin and {Servi J.}, Stevens and {Rushana C.}, Schroff and {Manjit K.}, Tanday and AD Wilson and {Jaap M.}, Middeldorp and {Peter L.}, Amlot and {Neil M.}, Steven",

note = "Publisher: Lippincott Williams & Wilkins",

year = "2009",

month = oct,

doi = "10.1097/TP.0b013e3181b9d918",

language = "English",

volume = "88",

pages = "1025 -- 1029",

journal = "Transplantation",

issn = "0041-1337",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

Lesley, R, E. Jane, T, Morgan, AJ, W. David, C, Finerty, S, Tintilade A., O-E, Karen, O, Collin, R, Servi J., S, Rushana C., S, Manjit K., T, Wilson, AD, Jaap M., M, Peter L., A & Neil M., S 2009, 'A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation', Transplantation, vol. 88, no. 8, pp. 1025 - 1029. https://doi.org/10.1097/TP.0b013e3181b9d918

TY - JOUR

T1 - A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation

AU - Lesley, Rees

AU - E. Jane, Tizard

AU - Morgan, AJ

AU - W. David, Cubitt

AU - Finerty, S

AU - Tintilade A., Oyewole-Eletu

AU - Karen, Owen

AU - Collin, Royed

AU - Servi J., Stevens

AU - Rushana C., Schroff

AU - Manjit K., Tanday

AU - Wilson, AD

AU - Jaap M., Middeldorp

AU - Peter L., Amlot

AU - Neil M., Steven

N1 - Publisher: Lippincott Williams & Wilkins

PY - 2009/10

Y1 - 2009/10

N2 - Vaccination against Epstein-Barr virus (EBV), inducing an antibody response to the envelope glycoprotein gp350,might protect EBV-negative children with chronic kidney disease from lymphoproliferative disease after transplantation. A phase I trial recruited children with chronic kidney disease to two successive cohorts given three injections of 12.5 µg (n=6) and 25 µg (n=10) recombinant gp350/alhydrogel vaccine more than 6 to 8 weeks. One in each cohort acquired wild EBV before the week 28 evaluation. Both doses were similarly immunogenic, inducing an IgG response in all 13 evaluable patients. Neutralizing antibodies were detected in four recipients (1/4 in the 12.5µg and 3/9 in the 25 µg cohort). Median time from first vaccination to transplantation was 24 weeks. Immune responses declined rapidly and were unlikely to affect posttransplant events. The vaccine was immunogenic but prolonged vaccination to time of transplantation, or improved adjuvants are required in future trials to reduce posttransplant EBV load and risk of lymphoproliferative disease.

AB - Vaccination against Epstein-Barr virus (EBV), inducing an antibody response to the envelope glycoprotein gp350,might protect EBV-negative children with chronic kidney disease from lymphoproliferative disease after transplantation. A phase I trial recruited children with chronic kidney disease to two successive cohorts given three injections of 12.5 µg (n=6) and 25 µg (n=10) recombinant gp350/alhydrogel vaccine more than 6 to 8 weeks. One in each cohort acquired wild EBV before the week 28 evaluation. Both doses were similarly immunogenic, inducing an IgG response in all 13 evaluable patients. Neutralizing antibodies were detected in four recipients (1/4 in the 12.5µg and 3/9 in the 25 µg cohort). Median time from first vaccination to transplantation was 24 weeks. Immune responses declined rapidly and were unlikely to affect posttransplant events. The vaccine was immunogenic but prolonged vaccination to time of transplantation, or improved adjuvants are required in future trials to reduce posttransplant EBV load and risk of lymphoproliferative disease.

U2 - 10.1097/TP.0b013e3181b9d918

DO - 10.1097/TP.0b013e3181b9d918

M3 - Article (Academic Journal)

C2 - 19855249

SN - 0041-1337

VL - 88

SP - 1025

EP - 1029

JO - Transplantation

JF - Transplantation

IS - 8

ER -

A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation

Abstract

Bibliographical note

UN SDGs

Access to Document

Handle.net

Fingerprint

Cite this